Related Experiment Video

Updated: Oct 7, 2025

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
10:07

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

13.5K

Targeting p21 for diabetes: Another choice of senotherapy

Hiroshi Kondoh1, Eiji Hara2

  • 1Geriatric Unit, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.

Cell Metabolism
|January 5, 2022
PubMed

Insights

Senotherapy eliminates senescent cells to treat age-related diseases. Researchers found senescent cells in fat tissue during obesity, and targeting them improved insulin resistance, offering a new obesity treatment.

Area of Science:

  • Cellular senescence
  • Metabolic diseases
  • Obesity research

Background:

  • Senotherapy is an emerging treatment for aging and lifestyle diseases.
  • Senescent cells accumulate with age and in disease states.
  • Obesity is linked to metabolic dysfunction and inflammation.

Purpose of the Study:

  • To investigate the presence and role of senescent cells in adipose tissue during obesity.
  • To explore senotherapy as a potential treatment for obesity-related metabolic complications.

Main Methods:

  • Identification and characterization of senescent cells expressing p21Cip1 in adipose tissue.
  • Genetic and pharmacological targeting of senescent cells.
  • Assessment of insulin resistance in obese models.

Main Results:

  • Senescent cells expressing high levels of p21Cip1 were found in adipose tissue of obese subjects.
  • Targeting these senescent cells, either genetically or pharmacologically, reduced insulin resistance.
  • Elimination of senescent cells improved metabolic parameters associated with obesity.

Conclusions:

  • Senescent cells in adipose tissue are a key factor in obesity-induced insulin resistance.
  • Targeting p21Cip1-expressing senescent cells represents a promising therapeutic strategy for metabolic complications of obesity.
  • Senotherapy holds potential for treating obesity and related metabolic disorders.

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

693
Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells11:13

Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells

Published on: April 7, 2016

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
433
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
334
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K